Genmab — Februar 2022
-
I stand by that assumption. We are gonna get close to a third BB i 2022 ?
-
or no 3 and 4
-
Aktier/tendens: Novo kan klare sig bedre end ellers grønt marked
https://www.proinvestor.com/investornyt/774816/aktier-tendens-novo-kan-klare-sig-bedre-end-ellers-gront-marked -
Åbner vi over 2300? Ja det må tiden jo vise, men det blive nok grønt
-
Aktier/åbning: Novo og Ørsted i udbrud i grønt C25
https://www.proinvestor.com/investornyt/774828/aktier-abning-novo-og-orsted-i-udbrud-i-gront-c25 -
https://www.proinvestor.com/boards/97931#postdiv100653 nye købs signaler - kurs 2647
-
sorry @StockBull , but we can not accept any targets below 3000
-
I will enjoy sandbox end of marts. I will get you a cold drink if your are right this time SB
-
Aktier/middag: Ørsted og Novo brænder igennem på grøn dag i C25
https://www.proinvestor.com/investornyt/774867/aktier-middag-orsted-og-novo-braender-igennem-pa-gron-dag-i-c25 -
AbbVie Pipeline Update https://investors.abbvie.com/static-files/886648b5-06d7-4c66-aaa3-7c01a0fd4cbe shows submission Epcoritamab 3L R/R DLBCL (for AA on Ph2 data) in 2022, but approval in
2023
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind